# 14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection

> **NCT06687499** · PHASE4 · COMPLETED · sponsor: **National Cheng-Kung University Hospital** · enrollment: 46 (actual)

## Conditions studied

- Helicobacter Pylori
- Drug Resistance, Multiple

## Interventions

- **DRUG:** Bismuth-based susceptibility-guided treatment

## Key facts

- **NCT ID:** NCT06687499
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-22
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-01-26
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06687499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06687499, "14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06687499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*